<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871364</url>
  </required_header>
  <id_info>
    <org_study_id>AA32215</org_study_id>
    <nct_id>NCT00871364</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Actavis Group hf 50 mg Venlafaxine Hydrochloride Tablets and Wyeth Pharmaceuticals (Effexor®) 50 mg Venlafaxine Hydrochloride Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to assess the single-dose relative bioavailability of Actavis Group&#xD;
      hf 50 mg venlafaxine hydrochloride tablets with Wyeth Pharmaceuticals (Effexor®) 50 mg&#xD;
      venlafaxine (as venlafaxine hydrochloride) tablets under fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.&#xD;
&#xD;
      Official Title: Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study&#xD;
      of Actavis Group hf 50 mg Venlafaxine Hydrochloride Tablets and Wyeth Pharmaceuticals&#xD;
      (Effexor®) 50 mg Venlafaxine Hydrochloride Tablets in Healthy Adult Volunteers under Fed&#xD;
      Conditions.&#xD;
&#xD;
      Further study details as provided by Actavis Elizabeth LLC:&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate and Extend of Absorption&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VENLAFAXINE TABLETS 50 mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Effexor® (venlafaxine HCl) Tablets equivalent to 50 mg venlafaxine, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VENLAFAXINE TABLETS 50 mg , single dose</intervention_name>
    <description>A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>venlafaxine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effexor® Tablets equivalent to 50 mg venlafaxine</intervention_name>
    <description>B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>venlafaxine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult male or female volunteers, 18-55 years of age.&#xD;
&#xD;
          -  Weighing at least 60 kg for males and 52 kg for females and within 15% of their ideal&#xD;
             weights (Table of &quot;Desirable Weights of Adults&quot;, Metropolitan Life Insurance Company,&#xD;
             1983).&#xD;
&#xD;
          -  Medically healthy subjects with clinically normal laboratory profiles, vital signs and&#xD;
             ECGs.&#xD;
&#xD;
          -  Females of childbearing potential were either sexually inactive (abstinent) for 14&#xD;
             days prior to the first dose, throughout the study and for 6 days following the last&#xD;
             dose or were using one of the following acceptable birth control methods:&#xD;
&#xD;
               -  surgically sterile (bilateral tubal ligation, hysterectomy, bilateral&#xD;
                  oophorectomy) 6 months minimum;&#xD;
&#xD;
               -  IUD in place for at least 3 months;&#xD;
&#xD;
               -  barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to&#xD;
                  the first dose, throughout the study and for 6 days following the last dose;&#xD;
&#xD;
               -  surgical sterilization of the partner (vasectomy for 6 months minimum);&#xD;
&#xD;
               -  hormonal contraceptives for at least 3 months prior to the first dose of the&#xD;
                  study and up to 6 days following the last dose. Other birth control methods may&#xD;
                  have been deemed acceptable. Postmenopausal women with amenorrhea for at least 2&#xD;
                  years were eligible.&#xD;
&#xD;
          -  Gave voluntary written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or&#xD;
             psychiatric disease.&#xD;
&#xD;
          -  In addition, history or presence of:&#xD;
&#xD;
               -  alcoholism or drug abuse within the past year;&#xD;
&#xD;
               -  hypersensitivity or idiosyncratic reaction to venlafaxine or other selective&#xD;
                  serotonin and norepinephrine reuptake inhibitors;&#xD;
&#xD;
               -  glaucoma.&#xD;
&#xD;
          -  Female subjects who were pregnant or lactating.&#xD;
&#xD;
          -  Subjects who tested positive at screening for HIV, HbsAg or HCV.&#xD;
&#xD;
          -  Subjects who received monoamine oxidase (MAO) inhibitors within 28 days prior to&#xD;
             dosing.&#xD;
&#xD;
          -  Subjects who used any drugs or substances known to be strong inhibitors of CYP enzymes&#xD;
             (formerly known as P450 enzymes) within 10 days prior to the first dose.&#xD;
&#xD;
          -  Subjects who used any drugs or substances known to be strong inducers of CYP enzymes&#xD;
             (formerly known as P450 enzymes) within 28 days prior to the first dose.&#xD;
&#xD;
          -  Subjects who donated 50 to 499 mL of blood within 30 days and more than 499 mL within&#xD;
             56 days prior to the first dose.&#xD;
&#xD;
          -  Subjects who, through completion of the study, would have donated in excess of:&#xD;
&#xD;
               -  500 mL of blood in 14 days; or&#xD;
&#xD;
               -  1500 mL of blood in 180 days; or&#xD;
&#xD;
               -  2500 mL of blood in 1 year.&#xD;
&#xD;
          -  Subjects whose PR interval is &gt;200 msec at screening and prior to dosing.&#xD;
&#xD;
          -  Subjects whose QTc interval is &gt;450 msec at screening and prior to dosing.&#xD;
&#xD;
          -  Subjects who completed another clinical trial within 28 days prior to the first dose.&#xD;
&#xD;
          -  Subjects who were on a special diet (for whatever reason) during the 28 days prior to&#xD;
             the first dose and throughout the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetano Morelli,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Saint-Laurent, Montreal</city>
        <state>Quebec</state>
        <zip>H4R 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>venlafaxine</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

